



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

### **ANSWERS TO REVIEWERS' COMMENTS**

*We are pleased to receive the reviewer's comments about our manuscript. We have made the following changes according to the reviewers' recommendations*

#### **REVIEWER 1.**

Kilic et al wrote a review about current strategies (adjuvant, neoadjuvant chemotherapy and radiotherapy) for advanced gastric cancer. Major comments: many reviews about this topic have been already published, therefore this review is not completely novel. Moreover, the review is too long and, thus, it may bore the reader. Minor comments. Authors should explicit the meaning of "D2 dissection". A minor linguistic revision is need.

#### **AUTHORS' RESPONSE 1.**

We appreciate the valuable comments of the reviewer on the content and the extent of the review. Thus we have omitted some details in both the adjuvant chemotherapy and chemoradiotherapy sections. The description for D2 dissection is added in page 4 (line 103-105). The revised form of the article has been edited by a professional service and the certificate is included in the files.

#### **REVIEWER 2.**

Dear Editor: I have read with much interest the manuscript entitled "Current adjuvant treatment modalities for gastric cancer: From history to future" by Leyla Kilic and coworkers. It is a very interesting topic for readers of WJGO. It is a very interesting topic for oncologist, gastroenterologist, Internal Medicine physician.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

### REVIEWER 3.

The article under the title CURRENT ADJUVANT TREATMENT MODALITIES FOR GASTRIC CANCER : FROM HISTORY TO THE FUTURE deals with a very interesting issue. The article is updated referring to recent trials and metanalyses. My only remark is at the section of adjuvant chemoradiotherapy the authors referred to surgery at different trials without describing the type of surgery since its an important issue for the survival whether you perform a gastrectomy D2 or D1.

AUTHORS' RESPONSE: We appreciate the reviewer's comments on description of the type of surgery in the adjuvant chemoradiotherapy trials. First of all, the definition for D2 dissection is added in page 4 (line 103-105). Furthermore the information about the type of surgery was included in the section when the researchers have pointed in the full-text of the articles (lines 273-274, 290-291, 315-316, 353-354, 410-412, 434-436). However the type of surgery was not mentioned in some of the adjuvant chemoradiotherapy trials so the information was missing in the article.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---